Compare Orion Office REIT Inc (ONL) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Orion Office REIT Inc vs GeneDx Holdings Corp — how do they compare? Orion Office REIT Inc trades at $2.17 (market cap $125.50M), while GeneDx Holdings Corp trades at $67.33 (market cap $2.02B). The key difference: GeneDx Holdings Corp is far larger — about 16.1× Orion Office REIT Inc's market cap, and Orion Office REIT Inc pays a 3.64% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Orion Office REIT Inc for 33 Days and GeneDx Holdings Corp for 19 Days on average.
| ONL | WGS | |
|---|---|---|
Market Cap | $125.50M | $2.02B |
Volume | 303,276 | 734,640 |
Sector | Real Estate | Health |
52-Week High | $3.00 | $167.51 |
52-Week Low | $1.93 | $34.51 |
Typical Hold Time | 33 Days | 19 Days |
Enterprise Value | $542.43M | $2.05B |
Dividend Yield | 3.64% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ONL trades at $2.20, down 3.08% today, with a bearish technical signal. The company shows declining revenue from $208M in 2022 to $148M in 2025 and persistent net losses, though Q2 2026 EPS beat expectations. Valuation metrics appear attractive with P/S of 0.88 and P/B of 0.2, but negative profitability metrics and high debt levels pose concerns. Recent news highlights strategic portfolio repositioning efforts.
Outlook remains challenging with ongoing revenue declines and negative margins, though deep valuation discounts may attract value investors. Key risks include high leverage, office sector exposure, and sustained profitability challenges. Analyst sentiment is mixed with 50% buy and 50% hold ratings.
GeneDx (WGS) trades at $67.73, down 1.17% with bearish technical signals despite recent earnings beats. The company shows strong revenue growth to $454M in 2026 but faces profitability challenges with a -23.4% net margin. Recent developments include new genomic testing products and hospital partnerships, while analyst consensus remains strongly bullish with a $81 price target.
The stock presents a growth story with expanding genomic testing volumes but carries significant execution risk given negative profitability metrics. Upside potential exists if management can translate revenue growth into sustainable profits, though current cash flow trends and high valuation multiples warrant caution for risk-averse investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Orion Office REIT Inc
Orion Office REIT Inc is a internally-managed REIT engaged in the ownership, acquisition, and management of a diversified portfolio of mission-critical and headquarters office buildings located in high quality suburban markets across the U.S. and leased primarily on a single-tenant net lease basis to creditworthy clients.
Read more on ONL →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
